Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association.

Gastroenterology. 2006 Mar;130(3):940-87. Review. No abstract available.

PMID:
16530532
[PubMed - indexed for MEDLINE]
2.

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association.

Gastroenterology. 2006 Mar;130(3):935-9. No abstract available.

PMID:
16530531
[PubMed - indexed for MEDLINE]
3.

[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].

Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W.

Rev Gastroenterol Mex. 2006 Jul-Sep;71(3):351-401. Review. Spanish. No abstract available.

PMID:
17140062
[PubMed - indexed for MEDLINE]
4.

[Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].

Rogler G.

Dtsch Med Wochenschr. 2008 Sep;133(38):1917-21. doi: 10.1055/s-0028-1085577. Epub 2008 Sep 10. Review. German. No abstract available.

PMID:
18785084
[PubMed - indexed for MEDLINE]
5.

Efficacy of conventional immunosuppressive drugs in IBD.

Caprilli R, Angelucci E, Cocco A, Viscido A, Zippi M.

Dig Liver Dis. 2004 Nov;36(11):766-80. Review.

PMID:
15571009
[PubMed - indexed for MEDLINE]
6.

Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.

Vincenti F.

Transplant Proc. 2001 Jun;33(4 Suppl):11S-18S. No abstract available.

PMID:
11406263
[PubMed - indexed for MEDLINE]
7.

A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.

Sandborn WJ.

Am J Gastroenterol. 1996 Mar;91(3):423-33. Review. No abstract available.

PMID:
8633486
[PubMed - indexed for MEDLINE]
8.

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.

Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S.

Aliment Pharmacol Ther. 2008 Sep 15;28(6):674-88. doi: 10.1111/j.1365-2036.2008.03753.x. Review.

PMID:
18532990
[PubMed - indexed for MEDLINE]
9.

Pharmacogenetics and inflammatory bowel disease: progress and prospects.

Ho GT, Lees C, Satsangi J.

Inflamm Bowel Dis. 2004 Mar;10(2):148-58. Review. No abstract available.

PMID:
15168816
[PubMed - indexed for MEDLINE]
10.

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.

Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR.

Gastroenterology. 2003 Aug;125(2):320-7.

PMID:
12891531
[PubMed - indexed for MEDLINE]
11.

General principles of medical therapy of inflammatory bowel disease.

Friedman S.

Gastroenterol Clin North Am. 2004 Jun;33(2):191-208, viii. Review.

PMID:
15177534
[PubMed - indexed for MEDLINE]
12.

Review article: remission rates achievable by current therapies for inflammatory bowel disease.

Peyrin-Biroulet L, Lémann M.

Aliment Pharmacol Ther. 2011 Apr;33(8):870-9. doi: 10.1111/j.1365-2036.2011.04599.x. Epub 2011 Feb 15. Review.

PMID:
21323689
[PubMed - indexed for MEDLINE]
13.

[Crohn's disease--standards of treatment 2004].

Kruis W.

Praxis (Bern 1994). 2005 Oct 12;94(41):1595-8. Review. German.

PMID:
16245637
[PubMed - indexed for MEDLINE]
14.

[Current status of treatment of inflammatory bowel disease].

Rodríguez-Moranta F, Soriano-Izquierdo A, Guardiola J.

Cir Esp. 2007 Nov;82(5):254-9. Review. Spanish.

PMID:
18021623
[PubMed - indexed for MEDLINE]
Free Article
15.

Review article: monitoring of immunomodulators in inflammatory bowel disease.

Aberra FN, Lichtenstein GR.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):307-19. Review.

PMID:
15709982
[PubMed - indexed for MEDLINE]
Free Article
16.

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y.

Clin Gastroenterol Hepatol. 2013 Apr;11(4):444-7. doi: 10.1016/j.cgh.2012.10.020. Epub 2012 Oct 24.

PMID:
23103905
[PubMed - indexed for MEDLINE]
17.

Newer treatments for inflammatory bowel disease.

Stotland BR, Lichtenstein GR.

Prim Care. 1996 Sep;23(3):577-608. Review.

PMID:
8888346
[PubMed - indexed for MEDLINE]
18.

Balancing efficacy and toxicity in kidney-transplant immunosuppression.

Leichtman AB.

N Engl J Med. 2007 Dec 20;357(25):2625-7. No abstract available.

PMID:
18094383
[PubMed - indexed for MEDLINE]
19.

Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.

Bousvaros A.

Expert Rev Clin Immunol. 2010 Jul;6(4):659-66. doi: 10.1586/eci.10.46. Review.

PMID:
20594138
[PubMed - indexed for MEDLINE]
20.

[Auto-immune hepatitis: therapeutic management].

Pariente A.

Gastroenterol Clin Biol. 2003 May;27(5 Suppl):B13-9. Review. French. No abstract available.

PMID:
12843932
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk